Treats plaque psoriasis. ANDA 217075, held by Padagis Israel. Tazarotene.
As of Nov 15, 2026, ANDA 217075 (Tazarotene), held by Padagis Israel, was first approved by FDA on Jul 15, 2024, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tazarotene0.05% · cream;topical | Tazarotene | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
